drug development

Rigel Pharmaceuticals (RIGL) Stock Skyrockets on Earnings Beat – Latest Drug Updates & Analyst Outlook

Stock Price & Recent Performance 📈 Rigel’s stock has been on a tear in 2025, reflecting its improving fundamentals. As of November 5, 2025, RIGL trades around $38/share, up over 30% in a single day after its blowout Q3 earnings report stockanalysis.com. The post-earnings volatility has been extreme – initially, shares fell ~7–8% in after-hours trading on Nov. 4 despite the strong results, possibly due to profit-taking or tempered forward outlook, dipping to about $30.32 investing.com. However, sentiment swiftly reversed: by the next trading session, buyers piled in, and Rigel stock skyrocketed to new multi-month highs. The stock is now

5 November 2025

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech stockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21 stockanalysis.com, versus

31 October 2025

Biotech · Healthcare Innovation · NASDAQ:RANI · Obesity Treatment · Pharmaceutical Industry · Stock Market News

NewAmsterdam Pharma (NAMS) Stock Soars on Cholesterol Drug Breakthrough – What Investors Should Know

Company Overview: History & Mission NewAmsterdam Pharma Company N.V. is a Netherlands-based biotech (with U.S. operations in Miami) on a mission to “change the landscape of lipid-lowering treatment” for cardiovascular disease newamsterdampharma.com. Founded in early 2020, the company sprang from the vision of Prof. John J.P. Kastelein – a world-renowned expert in lipid disorders – and venture capital firm Forbion newamsterdampharma.com. They acquired the rights to obicetrapib, a once-abandoned CETP inhibitor, from an Amgen subsidiary in 2020 newamsterdampharma.com. Soon after, Dr. Michael Davidson (a leading preventive cardiologist) joined as co-founder and CEO, bringing deep clinical expertise to the leadership team

11 October 2025

Biotech Innovations · Health Stocks · Investment Tips · NASDAQ:NAMS · Pharma Industry · Stock Market News

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platform protagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership &

11 October 2025

Biotech · Clinical Trials · Mergers & Acquisitions · Pharmaceuticals · Stock Market

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.

9 October 2025

Biotech News · Investment Insights · Mergers & Acquisitions · NASDAQ:AKRO · NYSE:NVO · Pharma Industry · Stock Market

Global Biotech & Health Roundup: Breakthrough Drugs, Big Deals & Policy Shifts (Aug 21–22, 2025)

Pharmaceutical Industry News (Approvals, Trials & Deals) Biotech Startups & Funding Highlights Medical Research Breakthroughs & Publications Healthcare Policy & Public Health Developments Regulatory Updates from Agencies (FDA, EMA, etc.) Sources: Scientific press releases, company announcements, major news outlets (Reuters, AP, HealthDay, FierceBiotech, etc.), and health agency briefs were used to compile this report reuters.com reuters.com ts2.tech interiusbio.com. Each item includes a citation link to the original source for further reading. This concludes the comprehensive roundup of biotech, pharma, medical, and health news from August 21–22, 2025.

22 August 2025

Biotech · Healthcare · Industry News · NASDAQ:GILD · NASDAQ:IONS · NASDAQ:PRGN · NASDAQ:XOMA · NYSE:JNJ · Pharmaceuticals · Policy